Omnigene Medical Technologies
  • We innovate for better Health

    A multidisciplinary approach to solve clinical needs

    Our expert team enables access to accurate, sensitive and innovative methods supporting research and diagnostics of clinical relevance.           

    CONTACT US

    or send us an email on scientific.support@genemt.com

  • We invest in research

    Research projects to optimise technologies and develop & validate test prototypes

    ​Our research scientists have ample experience in optimising molecular technologies, bead-based multiplex assay development, developing quality control material.  Areas include oncology, neuroscience and research on SARS-CoV-2 (COVID-19) induced immune response. 

  • We work with Partners

    Recognised by International Partners

    Fully supported by Luminex Corporation, ThermoFisher, NMI-TT, miRXES  

Products & Services

The year 2020 presented us with major challenges.  We are happy to announce that we secured freedom-to-operate in Europe for the first multiplex assay to classify breast cancer.   Ongoing projects include analysis of FFPE biopsies, xenograft classification, exosome research and many more.


Join us in our mission:

  • An RUO molecular classification of breast cancer is now approved for sale in Europe.
  • Our R&D embarked on setting up sensitive techniques to measure biomarkers in blood-derived exosomes.
  • Our professional team is seeking partnerships to enhance market entry and develop new products. 
  • Our commercial team is providing high quality reagents for research institutions, including cutting edge technologies and services.


Join Us

Research Projects & Innovations

M3 PROFILER

To synergise the advantages of microfluidics, and multiplex bead based assays, to measure biomarkers in blood-derived exosomes.

iMPACT

Innovative molecular profiling assays to classify tumours.  We developed multiplex assays for academic research and clinical laboratories.

CoV-plex

To develop a molecular test that measures COVID-19 (SARS-CoV-2) immune response for vaccine surveillance.



Bookind

To innovate a companion diagnostic product that predicts use of specific therapeutics in Epilepsy.



Who Are We ?

About Us

The executive team brings together a wealth of experience in health management, quality standards, commercial licensing, scientific excellence and product development & innovation.  Together with the scientific team the company invested in research projects to enable innovations and secured international reputation with more than 10 partners globally.

  • innovative cancer tests
  • accurate & sensitive measurements
  • enable use of low input, low quality precious patient material
  • clinical relevant solutions in oncology 
  • competitive prices
Get in Touch TODAY

10+

international partners

1000+

Hours of Research & Innovation

10+

Years Experience

Investment is the KEY to innovation

Innovation is the KEY to better Health

Help us make an impact - Follow us

What our partners have to say

Testimonial